Future studies aimed at elucidating how this compound binds to the estrogen receptors and the exact mechanism by which bonediol activates Nrf2-ARE will be beneficial to development of a potential new prostate cancer therapeutic. The gene discussed is NFE2L2; the disease is Familial prostate cancer.